launched on January 26, Krishna Ella the Chairman and Managing Director of
the company said. “Our nasal vaccine will be officially launched on January
26, on Republic Day,” Ella said in an interaction with students at the
India International Science Festival in Bhopal.The intranasal vaccine
stimulates a broad immune response, says the manufacturer, like
neutralizing IgG, mucosal IgA, and T cell responses. It initiates immune
responses in the nasal mucosa and can block infection and transmission of
COVID.It is needle free and hence eliminates the risks associated with
needle related injuries and infections.
Before getting iNCOVACC , need to inform the vaccination provider about the
regular medication you take. The persons who wish to take vaccine should
inform about any treatment for coagulation/bleeding disorder. Those who are
less than 18 years of age can not be administered iNCOVACC.
iNCOVACC will not be given to those who had severe allergic reaction to any
ingredients of the vaccine or those who had a severe allergic reaction
after a previous dose of this vaccine. Those who have an acute infection or
fever can not be given the nasal vaccine if the fever still persists in the
body.
iNCOVACC will be given as a 2-dose series. The gap between both the
consecutive doses will be 4 weeks.A total of 8 drops, 0.5 mL per dose, will
be given to the person; 4 drops will be given in each nostril.
